Moreover, KRT17’s regulatory role has been highlighted in tumor immunology, particularly colorectal cancer, where KRT17 interacts directly with the m6A reader YTHDF2, stabilizing CXCL10 mRNA and enhancing CD8+ T-cell recruitment to the tumor microenvironment, thus potentiating anti-tumor immune responses and efficacy of immune checkpoint blockade therapies (104, 164). This evidence concerns the gene CD8A and neoplasm.